CORE--CLINICAL RESEARCH DEVELOPMENT

阿尔茨海默病(AD)的持续科学进步依赖于 用于研究的患者和对照的可用性， 痴呆症的临床诊断、交流与协作 在从事不同方面工作的不同学科的调查人员之间 他的病。临床研究开发核心的主要目标是 促进遗传家系研究和其他多学科 Bryan ADRC通过提供所需的基本患者材料所做的努力 进行这些调查。临床研究有四个具体目标 核心： 1)为记忆障碍患者提供诊断性评估。我们 计划将重点放在持续的高质量患者评估上。我们也会 继续探索将我们的服务扩展到非裔美国人的方法 在该中心任职人数不足的老年人。 2)从患者基础、先证者和家庭中确定适合 阿尔茨海默病的基因家族研究。有50多个家庭 在有多代AD证据的中心登记 经尸检确认。我们计划继续开发其他 并评估这些参与者，无论是在 记忆障碍诊所，或者，为了患者的方便，在家里。 3)促进阿尔茨海默病的临床研究。这个 临床核心将继续成为美国医学会的研究资源 Bryan ADRC和研究资源批准的外部研究以及 覆核委员会。我们还致力于探索提高临床应用水平的方法 诊断(例如，计算机化评估、诊断算法) 优化提供给合作者的数据质量。 4)开展阿尔茨海默病治疗药物干预试验。 随着阿尔茨海默病生物学的进步，我们预计整个新的类别 化合物可能在不久的将来可用于测试。我们有一个 发展良好的基础设施，用于招募患者参加研究。 通过核心B的研究和资源审查委员会，我们计划 继续为有记忆的患者筛选有前景的药物方案 精神错乱。

The continuing scientific progress in Alzheimer's disease (AD) relies on the availability of patients and controls for study, the reliability of the clinical diagnoses of dementia, and the interchange and collaboration between investigators across disciplines working on different aspects of the illness. The main goal of the Clinical Research Development Core is to facilitate the genetic family studies and the other multidisciplinary efforts of the Bryan ADRC by providing the basic patient material needed for these investigations. There are four specific aims of the Clinical Core: 1) Provide diagnostic assessment of patients with memory complaints. We plan to focus on continued high quality patient evaluation. We also will continue to explore ways to extend our services" to African American elderly who have been under-represented in the Center. 2) Identify from the patient base, probands and families appropriate for genetic family studies of Alzheimer's disease. There are over 50 families enrolled in the center in which there is multigenerational evidence of AD with autopsy confirmation. We plan to continue to develop additional informative families and to evaluate these participants either in the Memory Disorders Clinic or, for patients convenience, in the home. 3) Facilitate clinical research studies of Alzheimer's disease. The Clinical Core will continue to be a resource to the research studies of the Bryan ADRC and to external studies approved by the Research Resource and Review Committee. We also aim to explore ways to enhance clinical diagnosis (e.g. computerized assessment, diagnostic algorithms) thereby optimizing the quality of the data provided to collaborators. 4) Conduct therapeutic drug intervention trials for Alzheimer's disease. With the advances in the biology of AD, we expect that whole new classes of compounds may become available for testing in the near future. We have a well developed infrastructure for recruiting patients into studies. Through the Research and Resource Review Committee of Core B we plan to continue to screen for promising drug protocols for patients with memory disorders.